Try the BMI Calculator Table of contents The 30-second answer The full SURMOUNT-1 dose-response data Why "highest dose = best" isn't always true The standard dose escalation schedule When to stop escalating: signs your current dose is working The 5 percent rule at month 3 and month 6 Why some patients don't need to reach 15 mg Side effects across the dose ladder Maintenance vs continued escalation FAQ The full SURMOUNT-1 dose-response data SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the phase 3 registration trial that earned Zepbound its FDA approval for weight management
Many patients report that gastrointestinal symptoms tend to improve over time as the body adapts to the medication
Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham heart study
All three tirzepatide doses were more effective than basal insulin both in reducing HbA 1c (mean differences ranging between 7.66 mmol/mol [0.70%] with tirzepatide 5 mg and 12.02 mmol/mol [1.09%] with tirzepatide 15 mg [ESM Fig
In a combined fertility and embryo-fetal development study in rats, subcutaneous doses of 0.01, 0.03 and 0.09 mg/kg/day (0.04-, 0.1-, and 0.4-fold the MRHD) were administered to male and female rats
These tools include: Weight Health Score: a science-based way to measure real progress At the center of the new experience is the new Weight Health Score, an evidence-based metric that turns daily habits into an easy-to-understand scoring system